Late pulmonary complications of treating Hodgkin lymphoma

Bleomycin-induced toxicity

Ádám Jóna, Zsófia Miltényi, Zsófia Ujj, Ildikó Garai, Mária Szilasi, A. Illés

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Survival of Hodgkin lymphoma (HL) patients has significantly improved in recent decades. The current first-line therapy is doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) ± irradiation and may cause pulmonary toxicity. Strategies to reduce late toxicity as well as increase survival rate are of interest.Patients and methods: Pulmonary function of previously treated HL patients was collected over a 12-month period using St. George Respiratory Questionnaire (SGRQ), chest X-ray, dynamic inhalation lung scintigraphy and spirometry.Results: A total of 137 patients' data were reviewed. Median time elapsed since diagnosis was 11 years (range was 2-30 years). Chest irradiation did not significantly worsen pulmonary function. Number of ABVD cycles with consequential bleomycin dose showed significant correlation with SGRQ total score in patients receiving ABVD plus chest irradiation (p = 0.01). Scintigraphy results correlated with bleomycin dose in patients receiving ABVD without chest irradiation (right side: p = 0.099, left side: p = 0.051).Discussion: An additive negative effect of chest irradiation was not confirmed as reflected in the literature; however, increasing cumulative bleomycin dose worsened pulmonary function.

Original languageEnglish
Pages (from-to)1291-1297
Number of pages7
JournalExpert Opinion on Drug Safety
Volume13
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Bleomycin
Hodgkin Disease
Thorax
Lung
Radionuclide Imaging
Dacarbazine
Vinblastine
Spirometry
Doxorubicin
Inhalation
Survival Rate
X-Rays
Survival

Keywords

  • Bleomycin
  • Hodgkin lymphoma
  • Pulmonary side effect
  • Scintigraphy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Late pulmonary complications of treating Hodgkin lymphoma : Bleomycin-induced toxicity. / Jóna, Ádám; Miltényi, Zsófia; Ujj, Zsófia; Garai, Ildikó; Szilasi, Mária; Illés, A.

In: Expert Opinion on Drug Safety, Vol. 13, No. 10, 01.10.2014, p. 1291-1297.

Research output: Contribution to journalArticle

Jóna, Ádám ; Miltényi, Zsófia ; Ujj, Zsófia ; Garai, Ildikó ; Szilasi, Mária ; Illés, A. / Late pulmonary complications of treating Hodgkin lymphoma : Bleomycin-induced toxicity. In: Expert Opinion on Drug Safety. 2014 ; Vol. 13, No. 10. pp. 1291-1297.
@article{e4779808265048eeba6863c5d12b208c,
title = "Late pulmonary complications of treating Hodgkin lymphoma: Bleomycin-induced toxicity",
abstract = "Introduction: Survival of Hodgkin lymphoma (HL) patients has significantly improved in recent decades. The current first-line therapy is doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) ± irradiation and may cause pulmonary toxicity. Strategies to reduce late toxicity as well as increase survival rate are of interest.Patients and methods: Pulmonary function of previously treated HL patients was collected over a 12-month period using St. George Respiratory Questionnaire (SGRQ), chest X-ray, dynamic inhalation lung scintigraphy and spirometry.Results: A total of 137 patients' data were reviewed. Median time elapsed since diagnosis was 11 years (range was 2-30 years). Chest irradiation did not significantly worsen pulmonary function. Number of ABVD cycles with consequential bleomycin dose showed significant correlation with SGRQ total score in patients receiving ABVD plus chest irradiation (p = 0.01). Scintigraphy results correlated with bleomycin dose in patients receiving ABVD without chest irradiation (right side: p = 0.099, left side: p = 0.051).Discussion: An additive negative effect of chest irradiation was not confirmed as reflected in the literature; however, increasing cumulative bleomycin dose worsened pulmonary function.",
keywords = "Bleomycin, Hodgkin lymphoma, Pulmonary side effect, Scintigraphy",
author = "{\'A}d{\'a}m J{\'o}na and Zs{\'o}fia Milt{\'e}nyi and Zs{\'o}fia Ujj and Ildik{\'o} Garai and M{\'a}ria Szilasi and A. Ill{\'e}s",
year = "2014",
month = "10",
day = "1",
doi = "10.1517/14740338.2014.946901",
language = "English",
volume = "13",
pages = "1291--1297",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Late pulmonary complications of treating Hodgkin lymphoma

T2 - Bleomycin-induced toxicity

AU - Jóna, Ádám

AU - Miltényi, Zsófia

AU - Ujj, Zsófia

AU - Garai, Ildikó

AU - Szilasi, Mária

AU - Illés, A.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Introduction: Survival of Hodgkin lymphoma (HL) patients has significantly improved in recent decades. The current first-line therapy is doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) ± irradiation and may cause pulmonary toxicity. Strategies to reduce late toxicity as well as increase survival rate are of interest.Patients and methods: Pulmonary function of previously treated HL patients was collected over a 12-month period using St. George Respiratory Questionnaire (SGRQ), chest X-ray, dynamic inhalation lung scintigraphy and spirometry.Results: A total of 137 patients' data were reviewed. Median time elapsed since diagnosis was 11 years (range was 2-30 years). Chest irradiation did not significantly worsen pulmonary function. Number of ABVD cycles with consequential bleomycin dose showed significant correlation with SGRQ total score in patients receiving ABVD plus chest irradiation (p = 0.01). Scintigraphy results correlated with bleomycin dose in patients receiving ABVD without chest irradiation (right side: p = 0.099, left side: p = 0.051).Discussion: An additive negative effect of chest irradiation was not confirmed as reflected in the literature; however, increasing cumulative bleomycin dose worsened pulmonary function.

AB - Introduction: Survival of Hodgkin lymphoma (HL) patients has significantly improved in recent decades. The current first-line therapy is doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) ± irradiation and may cause pulmonary toxicity. Strategies to reduce late toxicity as well as increase survival rate are of interest.Patients and methods: Pulmonary function of previously treated HL patients was collected over a 12-month period using St. George Respiratory Questionnaire (SGRQ), chest X-ray, dynamic inhalation lung scintigraphy and spirometry.Results: A total of 137 patients' data were reviewed. Median time elapsed since diagnosis was 11 years (range was 2-30 years). Chest irradiation did not significantly worsen pulmonary function. Number of ABVD cycles with consequential bleomycin dose showed significant correlation with SGRQ total score in patients receiving ABVD plus chest irradiation (p = 0.01). Scintigraphy results correlated with bleomycin dose in patients receiving ABVD without chest irradiation (right side: p = 0.099, left side: p = 0.051).Discussion: An additive negative effect of chest irradiation was not confirmed as reflected in the literature; however, increasing cumulative bleomycin dose worsened pulmonary function.

KW - Bleomycin

KW - Hodgkin lymphoma

KW - Pulmonary side effect

KW - Scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=84907270521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907270521&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.946901

DO - 10.1517/14740338.2014.946901

M3 - Article

VL - 13

SP - 1291

EP - 1297

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 10

ER -